Altimmune's Upcoming Investor Conferences
Altimmune, Inc. is gearing up for two notable investor conferences where members of the management team will be available for discussions. This presents a fantastic opportunity for investors and stakeholders to gain insights into the company’s exciting developments.
Annual Evercore HealthCONx Conference
On a significant day dedicated to healthcare discussions, Altimmune will participate in the Annual Evercore HealthCONx Conference. This event is scheduled to take place in Coral Gables, Florida. The company will engage in a Fireside Chat, delivering key insights into their operations and future directions. This chat will commence at 10:50 a.m. Eastern Time, aiming to attract significant attention from conference attendees.
Piper Sandler Annual Healthcare Conference
Following shortly after, Altimmune will also participate in the Piper Sandler Annual Healthcare Conference in New York. This event is poised to further highlight Altimmune’s commitment to its advancements in biopharmaceuticals. The Fireside Chat at this conference will occur at 3:30 p.m. Eastern Time, providing yet another platform for the company to showcase its dedication to innovation and transparency in the healthcare sector.
Webcast Access for Participants
Investors and interested parties can access the webcasts of these sessions through the Events section on Altimmune's website. This accessibility ensures that stakeholders can stay informed about the latest developments with the company, strengthening community engagement and investor relations.
Innovative Developments by Altimmune
Building on its reputation as a clinical-stage biopharmaceutical company, Altimmune focuses on developing next-generation peptide-based therapeutics. One of the significant advancements includes pemvidutide, a GLP-1/glucagon dual receptor agonist tailored for treating obesity and metabolic conditions. As the healthcare landscape continues to evolve, Altimmune is positioning itself at the forefront of innovative treatments that aim to address pressing health challenges.
Commitment to Transparency and Communication
Altimmune emphasizes its commitment to transparency and open communication with its investors and stakeholders. The management team’s participation in these conferences is part of its broader strategy to keep everyone informed about the company’s progress and the impact of its therapeutic developments.
Staying Connected with Altimmune
For those interested in following Altimmune’s journey, they can connect on various social media platforms, including LinkedIn and Twitter, where updates and insights are regularly shared. This digital presence allows stakeholders immediate access to company news and announcements.
Company Contact Information
Altimmune encourages any inquiries related to investor relations or further information to be directed to their Chief Financial Officer, Greg Weaver. He can be reached at 240-654-1450. Additionally, for specific investor queries, Lee Roth from Burns McClellan is available at 646-382-3403. Media inquiries can be sent to Danielle Cantey via phone at 619-826-4657.
Frequently Asked Questions
What is Altimmune known for?
Altimmune is recognized for its innovative development of peptide-based therapeutics aimed at treating obesity and metabolic disorders.
Where will Altimmune present next?
Altimmune will participate in the Annual Evercore HealthCONx Conference and the Piper Sandler Annual Healthcare Conference.
How can I access the presentations?
Webcasts of the presentations can be accessed through the Events section on Altimmune's website.
What is pemvidutide?
Pemvidutide is Altimmune's GLP-1/glucagon dual receptor agonist, targeting obesity and metabolic diseases.
How can I contact Altimmune?
To reach Altimmune, you can contact Greg Weaver, CFO, at 240-654-1450 for investor-related inquiries.
